Should I buy Dexcom (DXCM) stock or is it too late?

Dexcom · Health Care · price $89

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Deutsche Bank — 72% of its targets hit on this sector (291 calls tested). It aims for $86 (-3.7 %), call made on June 24, 2026, maturing on June 24, 2027 (65 d ago).

The 13 reliable analysts $90+0.8 %

The 3 other firms $80-10 %

How to read it: the 13 reliable firms are not filtered by optimism — 9 aim above the price, 4 below, hence their $90 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Dexcom

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
B of A Securities	100 %	+59.1 %	6	$80 -10%
JP Morgan	92 %	+53.0 %	12	$82 -8%
Canaccord Genuity	70 %	+36.3 %	23	$90 +1%
Stifel	73 %	+32.0 %	11	$95 +6%
Raymond James	63 %	+24.4 %	30	$102 +14%
BTIG	67 %	+7.0 %	9	$90 +1%
Piper Sandler	59 %	+5.3 %	17	$95 +6%
Citigroup	55 %	-2.0 %	11	$88 -1%

In short — Should you invest in Dexcom? Is it too late, still worth it? Analysts are overwhelmingly positive (88% buy, median target $90, i.e. +1%). But the valuation is stretched (P/E ~35), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

88% of analysts rate it a buy (Buy consensus, 16 ratings) — a sign of market conviction.
5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

Even the most reliable firm on DXCM, B of A Securities (100% hit rate, 6 scored calls), only targets $80 (call made on May 18, 2026, maturing on May 18, 2027) (-10%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 16 ratings, 1 is neutral and 1 is a sell.
Limited upside: the median target is only +1% from the current price.
High valuation (P/E ~35): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on DXCM

Median target $90 (+1%) · 16 ratings · Buy consensus

Strong Buy00%

Buy1488%

Hold16%

Sell16%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Dexcom now?

We won't decide for you. The facts: 88% of analysts rate it a buy, median target $90 (+1%), and B of A Securities (most reliable on DXCM, 100%) targets $80. Weigh that against valuation (P/E ~35). This is not personalized advice.

Is it too late to invest in Dexcom?

The stated upside is small: the median target ($90) sits just +1% from the price ($89) (most reliable on DXCM: B of A Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Dexcom still worth investing in?

It depends on the gap between the price ($89) and its estimated value: analysts target $90 on median (+1%), with 88% buys (most reliable on DXCM: B of A Securities, 100%). Cross-check with their real reliability on DXCM and the cautions above. Information, not advice.

What's the main risk in buying DXCM?

Even the most reliable firm on DXCM, B of A Securities (100% hit rate, 6 scored calls), only targets $80 (call made on May 18, 2026, maturing on May 18, 2027) (-10%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Dexcom profile (consensus, analyst reliability, price target, performance).